Celltech to quit Chirotech for pounds 59m
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.CELLTECH CHIROSCIENCE, the UK's leading biotechnology technology, is to exit compound manufacturing, after Ascot, a diversified holding company, exercised an option to acquire an outstanding stake in its ChiroTech subsidiary. The consideration is pounds 59m.
The move follows Ascot's acquisition of a 30 per cent stake, together with rights to acquire the remainder, of ChiroTech in September last year for pounds 30m. Celltech's shares fell 13.5p to 460p on the announcement, with analysts saying the price did not correspond with that of the initial 30 per cent stake.
Peter Allen, Celltech's chief operating officer, defended the price, however. "The initial pounds 30m was for an option over the remainder in addition to a 30 per cent stake." Although the initial deal obliged Celltech to sell its remaining stake to Ascot at a price decided by an independent valuer, the parties agreed to negotiate the consideration instead.
Celltech will retain liability for a lawsuit filed against ChiroTech by Resolution Chemicals, a UK pharmaceuticals company, which claims Chirotech breached a supply agreement.
Celltech, formed from the merger of Celltech and Chiroscience in June, said it could now focus on drug discovery and development.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments